Akebia Therapeutics, Inc.
DE ˙ DB ˙ US00972D1054
0,83 € ↓ -0,02 (-2,69%)
2026-06-03
DEL PRIS
SecurityDE:AX9 / Akebia Therapeutics, Inc.
InstitutionSquarepoint Ops LLC
Latest Disclosed Ownership422,828 shares
Latest Disclosed Value $ 587,731
Squarepoint Ops LLC reports 65.43% decrease in ownership of AX9 / Akebia Therapeutics, Inc.

On May 15, 2026 - Squarepoint Ops LLC filed a 13F-HR form disclosing ownership of 422,828 shares of Akebia Therapeutics, Inc. (DE:AX9) valued at $482,447 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 1,223,027 shares of Akebia Therapeutics, Inc.. This represents a change in shares of -65.43% during the quarter. The current value of the position is $351,286 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F AKEBIA THREAPEUTICS COM 00972D105 422,828 -800,199 -65.43 588 -70.19 0.0007
2026-02-13 2025-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 1,223,027 444,498 57.09 1,969 -7.34 0.0021
2025-11-14 2025-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 778,529 617,337 382.98 2,125 262.63 0.0021
2025-08-27 2025-06-30 13F/A-1 AKEBIA THERAPEUTICS COM 00972D105 161,192 116,149 257.86 587 581.40 0.0006
2025-08-14 2025-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 161,192 116,149 587 0.0006
2025-08-27 2025-03-31 13F/A-1 AKEBIA THERAPEUTICS COM 00972D105 45,043 45,043 86 0.0001
2025-05-15 2025-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 45,043 45,043 86 0.0001
2025-02-14 2024-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 0 -140,167 -100.00 0 -100.00
2024-11-14 2024-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 140,167 101,612 263.55 185 374.36 0.0003
2024-08-14 2024-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 38,555 -216,109 -84.86 39 -91.63 0.0001
2024-05-15 2024-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 254,664 224,108 733.43 466 1,159.46 0.0008
2024-02-14 2023-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 30,556 30,556 38 0.0001
2022-11-14 2022-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 0 -29,471 -100.00 0 -100.00
2022-08-15 2022-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 29,471 -28,825 -49.45 10 -76.19 0.0001
2022-05-16 2022-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 58,296 32,044 122.06 42 -28.81 0.0002
2022-02-14 2021-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 26,252 26,252 59 0.0002
2021-08-16 2021-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 0 -238,876 -100.00 0 -100.00
2021-05-17 2021-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 238,876 -179,904 -42.96 809 -31.03 0.0047
2021-02-16 2020-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 418,780 -606,616 -59.16 1,173 -54.43 0.0088
2020-11-16 2020-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 1,025,396 931,780 995.32 2,574 102.52 0.0347
2020-08-14 2020-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 93,616 -127,493 -57.66 1,271 -24.16 0.0206
2020-05-15 2020-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 221,109 107,989 95.46 1,676 134.41 0.0429
2020-02-14 2019-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 113,120 -53,404 -32.07 715 9.49 0.0043
2019-11-14 2019-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 166,524 -118,521 -41.58 653 -52.68 0.0058
2019-08-14 2019-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 285,045 174,503 157.86 1,380 52.49 0.0134
2019-05-15 2019-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 110,542 -47,463 -30.04 905 3.55 0.0096
2019-02-14 2018-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 158,005 73,142 86.19 874 16.69 0.0102
2018-11-14 2018-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 84,863 4,683 5.84 749 -6.37 0.0090
2018-08-14 2018-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 80,180 28,380 54.79 800 61.94 0.0106
2018-05-15 2018-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 51,800 13,996 37.02 494 -12.10 0.0078
2018-02-14 2017-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 37,804 37,804 -27.02 562 13.77 0.0098
2017-05-15 2017-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 0 -18,462 -100.00 0 -100.00
2017-02-14 2016-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 18,462 18,462 192 0.0079
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.